Harvard Bioscience vs Mdxhealth SA
Mdxhealth SA is the larger business, with $108m of revenue in fiscal 2025 against $86.5m for Harvard Bioscience (1.2 times as much). Mdxhealth SA grew faster (19.8% against -8.1%). Mdxhealth SA kept more of each dollar of sales as profit: a net margin of -31.1% against -65.5%.
| Latest fiscal year | Harvard BioscienceHBIO, 2025 | Mdxhealth SAMDXH, 2025 |
|---|---|---|
| Revenue | $86.5m | $108m |
| Revenue growth | -8.1% | 19.8% |
| Net income | −$56.7m | −$33.5m |
| Operating margin | -56.1% | -13.4% |
| Net margin | -65.5% | -31.1% |
| Return on equity | -147.1% | — |
| Free cash flow | $5.5m | −$3.3m |
| Cash | $8.6m | $29.0m |
| Total debt | $40.0m | $76.2m |
| Debt to equity | 291.2% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 339 | — |
| Market value | $40.1m | $7.9m |
| Price vs our value range | — | — |
| Moat score | 56 (Moderate) | — |
| Insider trades, 12 months | 5 buys, 0 sales | 1 buys, 0 sales |